WO2007064776A3 - Markers for breast cancer - Google Patents

Markers for breast cancer Download PDF

Info

Publication number
WO2007064776A3
WO2007064776A3 PCT/US2006/045812 US2006045812W WO2007064776A3 WO 2007064776 A3 WO2007064776 A3 WO 2007064776A3 US 2006045812 W US2006045812 W US 2006045812W WO 2007064776 A3 WO2007064776 A3 WO 2007064776A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
markers
methods
prognosing
polymorphisms
Prior art date
Application number
PCT/US2006/045812
Other languages
French (fr)
Other versions
WO2007064776A2 (en
Inventor
David Cox
Dennis Ballinger
Bruce Ponder
Doug Easton
Original Assignee
Perlegen Sciences Inc
Univ Cambridge
David Cox
Dennis Ballinger
Bruce Ponder
Doug Easton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008543446A priority Critical patent/JP5394069B2/en
Priority to CA2631621A priority patent/CA2631621C/en
Application filed by Perlegen Sciences Inc, Univ Cambridge, David Cox, Dennis Ballinger, Bruce Ponder, Doug Easton filed Critical Perlegen Sciences Inc
Priority to KR1020137020281A priority patent/KR101472701B1/en
Priority to EP06838661A priority patent/EP1954834B1/en
Priority to AU2006320559A priority patent/AU2006320559B2/en
Priority to KR1020137031549A priority patent/KR101542677B1/en
Priority to KR1020087015808A priority patent/KR101445400B1/en
Priority to CN2006800517100A priority patent/CN101535500B/en
Priority to DK06838661.4T priority patent/DK1954834T3/en
Publication of WO2007064776A2 publication Critical patent/WO2007064776A2/en
Publication of WO2007064776A3 publication Critical patent/WO2007064776A3/en
Priority to IL191566A priority patent/IL191566A/en
Priority to HK09101235.4A priority patent/HK1121499A1/en
Priority to IL227563A priority patent/IL227563A/en
Priority to IL227564A priority patent/IL227564A/en
Priority to IL227562A priority patent/IL227562A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Sustainable Development (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.
PCT/US2006/045812 2005-11-29 2006-11-29 Markers for breast cancer WO2007064776A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DK06838661.4T DK1954834T3 (en) 2005-11-29 2006-11-29 breast Cancer Markers
CN2006800517100A CN101535500B (en) 2005-11-29 2006-11-29 Markers for breast cancer
KR1020137020281A KR101472701B1 (en) 2005-11-29 2006-11-29 Markers for breast cancer
CA2631621A CA2631621C (en) 2005-11-29 2006-11-29 Markers for breast cancer including rs2981582
AU2006320559A AU2006320559B2 (en) 2005-11-29 2006-11-29 Markers for breast cancer
KR1020137031549A KR101542677B1 (en) 2005-11-29 2006-11-29 Markers for breast cancer
KR1020087015808A KR101445400B1 (en) 2005-11-29 2006-11-29 Markers for breast cancer
JP2008543446A JP5394069B2 (en) 2005-11-29 2006-11-29 Markers about breast cancer
EP06838661A EP1954834B1 (en) 2005-11-29 2006-11-29 Markers for breast cancer
IL191566A IL191566A (en) 2005-11-29 2008-05-20 Method of identifying the risk of a human for developing a breast cancer phenotype
HK09101235.4A HK1121499A1 (en) 2005-11-29 2009-02-10 Markers for breast cancer
IL227563A IL227563A (en) 2005-11-29 2013-07-21 Markers for breast cancer
IL227564A IL227564A (en) 2005-11-29 2013-07-21 Markers for breast cancer
IL227562A IL227562A (en) 2005-11-29 2013-07-21 Markers for breast cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74097105P 2005-11-29 2005-11-29
US60/740,971 2005-11-29
US78148306P 2006-03-10 2006-03-10
US60/781,483 2006-03-10

Publications (2)

Publication Number Publication Date
WO2007064776A2 WO2007064776A2 (en) 2007-06-07
WO2007064776A3 true WO2007064776A3 (en) 2007-12-06

Family

ID=38092781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/045812 WO2007064776A2 (en) 2005-11-29 2006-11-29 Markers for breast cancer

Country Status (11)

Country Link
US (8) US20070166738A1 (en)
EP (5) EP2463388B1 (en)
JP (2) JP5394069B2 (en)
KR (3) KR101472701B1 (en)
CN (4) CN103710429B (en)
AU (1) AU2006320559B2 (en)
CA (2) CA3046754A1 (en)
DK (5) DK2463388T3 (en)
HK (2) HK1121499A1 (en)
IL (4) IL191566A (en)
WO (1) WO2007064776A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
EP2463388B1 (en) 2005-11-29 2017-11-22 Cambridge Enterprise Limited Markers for breast cancer
GB0716947D0 (en) * 2007-08-31 2007-10-10 Scottish Health Innovations Lt Genetic analysis
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US8367415B2 (en) * 2008-09-05 2013-02-05 University Of South Carolina Specific gene polymorphisms in breast cancer diagnosis, prevention and treatment
EP2438193B1 (en) 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
US20140023589A1 (en) * 2011-02-09 2014-01-23 Cancer Research Technology Limited Frmd4a antagonists and their uses
KR20120124507A (en) * 2011-05-02 2012-11-14 사회복지법인 삼성생명공익재단 Method for predicting chronic myeloid leukemia risk and kit for diagnosing chronic myeloid leukemia risk using thereof
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
CN104178567B (en) * 2014-07-22 2016-01-20 南京医科大学 A kind of SNP mark relevant to Computer-aided Diagnosis of Breast Cancer and application thereof
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
CN107760688A (en) * 2016-08-18 2018-03-06 深圳华大基因研究院 A kind of BRCA2 gene mutation bodies and its application
CN107760687A (en) * 2016-08-18 2018-03-06 深圳华大基因研究院 Gene mutation body and its application
CN106520957B (en) * 2016-11-18 2019-10-22 深圳市第二人民医院 The susceptible SNP site detection reagent of DHRS7 and its kit of preparation
CN106399304B (en) * 2016-11-18 2019-02-01 深圳市第二人民医院 A kind of SNP marker relevant to breast cancer
CN108277277B (en) * 2018-01-04 2020-11-03 北京大学深圳医院（北京大学深圳临床医学院） Marker for evaluating familial breast cancer risk and application thereof
US10692605B2 (en) 2018-01-08 2020-06-23 International Business Machines Corporation Library screening for cancer probability
TWI709188B (en) 2018-09-27 2020-11-01 財團法人工業技術研究院 Fusion-based classifier, classification method, and classification system
US20230170045A1 (en) * 2020-04-20 2023-06-01 Myriad Genetics, Inc. Comprehensive polygenic risk prediction for breast cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108910A1 (en) * 2001-07-27 2003-06-12 Toland Amanda E. STK15 (STK6) gene polymorphism and methods of determining cancer risk

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617281A5 (en) 1977-07-29 1980-05-14 Bbc Brown Boveri & Cie
US4240602A (en) 1979-03-19 1980-12-23 The Babcock & Wilcox Company Support device for a pressure vessel
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
DE4019005C2 (en) 1990-06-13 2000-03-09 Finnigan Mat Gmbh Devices for analyzing high mass ions
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE4331670A1 (en) 1993-09-17 1995-03-23 Hoechst Ag Antisense oligonucleotides against HSV-1 and the preparation thereof
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP3898228B2 (en) 1996-04-12 2007-03-28 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク Detection probes, kits and assays
CA2257109C (en) 1996-06-04 2009-10-06 University Of Utah Research Foundation Monitoring hybridization during pcr
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
GB9620749D0 (en) 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
JP2001503276A (en) * 1996-11-07 2001-03-13 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン Breast cancer susceptibility diagnostic assay
US6017758A (en) 1997-02-20 2000-01-25 Vanderbilt University DMNPE caged nucleic acid and vector
US6013449A (en) 1997-11-26 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Probe-based analysis of heterozygous mutations using two-color labelling
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
US6037130A (en) 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
WO2000033161A2 (en) 1998-12-02 2000-06-08 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
JP2003526367A (en) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド RNA interference method and RNA interference composition
WO2001070949A1 (en) 2000-03-17 2001-09-27 Benitec Australia Ltd Genetic silencing
EP2345742B1 (en) 2000-03-30 2014-06-11 The Whitehead Institute for Biomedical Research RNA sequence-specific mediators of RNA interference
WO2002008467A1 (en) 2000-07-25 2002-01-31 Dz Genes Llc DIAGNOSTIC POLYMORPHISMS FOR THE ecNOS PROMOTER
US6498035B1 (en) 2000-09-08 2002-12-24 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK3 expression
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6395544B1 (en) 2000-10-11 2002-05-28 Isis Pharmaceuticals, Inc. Antisense modulation of BCAS1 expression
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US7529685B2 (en) * 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US6740510B2 (en) 2001-09-05 2004-05-25 Perlegen Sciences, Inc. Methods for amplification of nucleic acids
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) * 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
US20050064442A1 (en) * 2002-11-25 2005-03-24 Roth Richard B. Methods for identifying risk of breast cancer and treatments thereof
US20040210400A1 (en) * 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20050019787A1 (en) * 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US20040229224A1 (en) * 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) * 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
AU2004271164A1 (en) * 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
EP2463388B1 (en) * 2005-11-29 2017-11-22 Cambridge Enterprise Limited Markers for breast cancer
JP2010512729A (en) 2006-06-23 2010-04-30 インタージェネティクス， インコーポレイテッド A genetic model for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
AU2008231425B2 (en) 2007-03-26 2014-03-20 Decode Genetics Ehf Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EA018444B1 (en) 2007-05-25 2013-08-30 Декоуд Дженетикс Ехф. GENETIC VARIANTS ON Chr 5p12 AND 10q26 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT
CA2693783A1 (en) 2007-07-11 2009-01-15 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
CN102171697A (en) 2008-08-08 2011-08-31 纳维哲尼克斯公司 Methods and systems for personalized action plans
EP2335174A1 (en) 2008-09-12 2011-06-22 Navigenics INC. Methods and systems for incorporating multiple environmental and genetic risk factors
EP2438193B1 (en) * 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
WO2013151413A1 (en) 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
JP2019054308A (en) 2016-01-26 2019-04-04 シャープ株式会社 Base station device, terminal device, and communication method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108910A1 (en) * 2001-07-27 2003-06-12 Toland Amanda E. STK15 (STK6) gene polymorphism and methods of determining cancer risk

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI SNP [online] 29 June 2003 (2003-06-29), XP008117794, Database accession no. (rs2981582) *
TANNHEIMER S.L. ET AL.: "Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE", BREAST CANCER RES., vol. 2, 24 May 2000 (2000-05-24), pages 311 - 320, XP021027060 *

Also Published As

Publication number Publication date
EP2463388B1 (en) 2017-11-22
EP2468901B1 (en) 2017-04-05
DK2458017T3 (en) 2017-07-03
CN103710430A (en) 2014-04-09
US20200040402A1 (en) 2020-02-06
US9068229B2 (en) 2015-06-30
US20090239763A1 (en) 2009-09-24
CA2631621A1 (en) 2007-06-07
CN103710429B (en) 2016-03-30
KR20130096768A (en) 2013-08-30
DK2463387T3 (en) 2017-01-09
US9702011B2 (en) 2017-07-11
US20090239226A1 (en) 2009-09-24
DK2468901T3 (en) 2017-07-17
US20150354010A1 (en) 2015-12-10
HK1121499A1 (en) 2009-04-24
US9051617B2 (en) 2015-06-09
JP5394069B2 (en) 2014-01-22
KR20080080597A (en) 2008-09-04
KR101542677B1 (en) 2015-08-06
JP5873835B2 (en) 2016-03-01
CN103710428B (en) 2016-03-30
CN101535500A (en) 2009-09-16
IL191566A (en) 2013-08-29
JP2009519707A (en) 2009-05-21
CN103710428A (en) 2014-04-09
WO2007064776A2 (en) 2007-06-07
EP2468901A2 (en) 2012-06-27
CA3046754A1 (en) 2007-06-07
KR20130136594A (en) 2013-12-12
IL191566A0 (en) 2008-12-29
EP2468901A3 (en) 2012-09-26
IL227562A (en) 2015-03-31
EP2463388A1 (en) 2012-06-13
EP2463387B1 (en) 2016-09-21
IL227563A (en) 2014-12-31
EP1954834A2 (en) 2008-08-13
EP2458017A1 (en) 2012-05-30
EP1954834B1 (en) 2012-08-08
EP1954834A4 (en) 2009-11-11
AU2006320559B2 (en) 2012-01-19
JP2013188223A (en) 2013-09-26
US20110015092A1 (en) 2011-01-20
CN103710430B (en) 2016-03-30
DK2463388T3 (en) 2018-02-26
US20170275707A1 (en) 2017-09-28
EP2458017B1 (en) 2017-03-15
CA2631621C (en) 2019-08-06
CN103710429A (en) 2014-04-09
KR101445400B1 (en) 2014-10-01
EP2463387A1 (en) 2012-06-13
DK1954834T3 (en) 2012-11-26
KR101472701B1 (en) 2014-12-15
IL227564A (en) 2014-12-31
AU2006320559A1 (en) 2007-06-07
CN101535500B (en) 2013-12-11
US20090208962A1 (en) 2009-08-20
HK1172064A1 (en) 2013-04-12
US10407738B2 (en) 2019-09-10
US20070166738A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2007064776A3 (en) Markers for breast cancer
WO2007100919A3 (en) Markers for addiction
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008067065A3 (en) Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009036427A3 (en) Prostate cancer biomarkers
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
IL185189A0 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2008094545A3 (en) Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
WO2007093657A3 (en) Method for the molecular diagnosis of prostate cancer and kit for implementing same
WO2009029550A3 (en) Highly sensitive system and methods for analysis of prostate specific antigen (psa)
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
HK1145342A1 (en) Prognosis prediction for melanoma cancer
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2009014565A3 (en) Methods for diagnosing and treating astrocytomas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680051710.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006320559

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 191566

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008543446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2631621

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006838661

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006320559

Country of ref document: AU

Date of ref document: 20061129

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087015808

Country of ref document: KR